Prostascint

 

Topic mentions per year

Topic mentions per year

1997-2015
02419972015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
PURPOSE To evaluate, in a prospective study, the use of (111)In-capromab pendetide (ProstaScint) scan to guide the delivery of a… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2011
2011
PURPOSE To evaluate the clinical utility of capromab pendetide imaging with single photon emission computed tomography… (More)
Is this relevant?
Review
2007
Review
2007
Cancer of the prostate is the most common cancer in males accounting for 33% of newly diagnosed cases. It is the second leading… (More)
Is this relevant?
Review
2005
Review
2005
PURPOSE OF REVIEW Despite marked stage migration, approximately a third of patients with clinically organ-confined prostate… (More)
Is this relevant?
2004
2004
Indium In 111 capromab pendetide (ProstaScint(R); Cytogen Corporation, Princeton, NJ), a radiolabeled monoclonal antibody to… (More)
Is this relevant?
2001
2001
We describe our initial experience using ProstaScint scanning in addition to conventional imaging modalities for staging of high… (More)
Is this relevant?
2000
2000
PURPOSE Whole-body, regional planar, and SPECT imaging using the In-111-labeled monoclonal antibody capromab pendetide (In-111… (More)
Is this relevant?
2000
2000
We report on the demonstration of nonspecific accumulation of indium-111 capromab pendetide (ProstaScint) in neurofibromas in a… (More)
Is this relevant?
2000
2000
PURPOSE Indium 111 capromab pendetide radioimmunoscintigraphy (ProstaScint) has been used to detect occult recurrent carcinoma… (More)
Is this relevant?
1998
1998
BACKGROUND ProstaScint (Cytogen Corporation, Princeton, NJ) murine monoclonal antibody imaging is FDA-approved for imaging of… (More)
Is this relevant?